CRISPR Therapeutics AG
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-91.2M | $-122.9M | $-130.6M | $-106.4M | $-208.5M | $-136.0M | $-37.3M | $-85.9M |
| Depreciation & Amortization | $4.3M | $4.3M | $5.7M | $4.4M | $4.6M | $4.7M | $4.8M | $4.7M |
| Depreciation | $4.3M | $4.3M | $5.7M | $4.4M | $4.6M | $4.7M | $4.8M | $4.8M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $17.3M | $16.3M | $18.1M | $16.6M | $17.6M | $20.2M | $21.9M | $21.5M |
| Net Cash from Operating Activities | $-83.5M | $-108.9M | $-92.6M | $-84.6M | $-113.9M | $-53.9M | $-50.0M | $-106.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-55.7M | $-410.7M | $37.2M | $-119.2M | $70.0M | $-19.8M | $105.8M | $-161.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $7.2M | $591.9M | $116.4M | $296.8M | $2.3M | $10.6M | $16.9M | $9.6M |
| Net Change in Cash | $-132.0M | $72.2M | $61.1M | $92.9M | $-41.6M | $-63.1M | $72.6M | $-258.8M |
| Free Cash Flow | $-84.1M | $-109.4M | $-93.1M | $-84.7M | $-114.0M | $-54.2M | $-50.3M | $-107.1M |